Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

Inclusion Criteria: * Male or female; * ≥18 to ≤75 years of age; * Diagnosis of TMA based on presence of: * Thrombocytopenia, defined as a platelet count \<100 x 109 per liter; * Microangiopathic hemolytic anemia, defined by negative findings on direct antiglobulin test, and evidence of accelerated red blood cell (RBC) production and destruction); AND * Absence of a clinically apparent alternative explanation for thrombocytopenia and anemia, e.g., disseminated intravascular coagulation (DIC), eclampsia, HELLP syndrome, Evans syndrome; * Females: non-pregnant and commit to use of effective, redundant methods of contraception (i.e., for both self and male partner) throughout the study and for at least 30 days after discontinuation of study drug treatment; * Males: commit to use of a medically acceptable contraceptive (abstinence or use of a condom with spermicide) throughout the study and for at least 30 days after discontinuation of study drug treatment; * Not received an unlicensed investigational agent (drug, device, or blood-derived product) within 30 days prior to randomization, and may not receive such an investigational agent in the 30 days post-randomization (note: investigational use for treatment of TMA of a licensed immunomodulator, e.g., rituximab, is permitted at any time relative to randomization); * Capable of understanding and complying with the protocol, and he/she (or a legal representative) must have signed the informed consent document prior to performance …